Navigation Links
Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles
Date:10/15/2008

isease, but does so in a larger patient population and in a randomized fashion," commented Morton Kern, MD, professor of medicine and associate chief, Division of Cardiology, University of California, Irvine.

FAME randomized 1005 patients diagnosed with multi-vessel coronary artery disease at 20 European and US centers to either angiography-guided PCI (n=496) or FFR-guided PCI (n=509) all using current DES regimens. FAME's objective was to compare angiographic guidance to FFR guidance and to determine which coronary lesions required revascularization. FAME demonstrated that FFR- guidance in routine multi-vessel PCI resulted in clinically-superior outcomes and reduced the composite of death, documented myocardial infarction, and repeat revascularization by 30 percent at one year. The study also demonstrated that adhering to an FFR-guided regimen for multi-vessel disease is cost beneficial to the hospital and payers by reducing procedural costs ($5,332 vs. $6,007), lowering average length of hospitalization (3.4 days vs. 3.7 days), and reducing the number of drug eluting-stents necessary per patient (1.9 vs. 2.7). The data also showed that the implementation of FFR did not add time to the multi-vessel PCI procedure.

DEFER

DEFER is a landmark study demonstrating that patients with intermediate disease not treated with PCI based on FFR guidance achieved long-term outcomes out to five years equivalent to patients who underwent PCI for similar intermediate lesions. DEFER outlines a revascularization strategy for angiographically equivocal stenoses that deploys FFR technology to identify and treat only those lesions producing reversible ischemia. The Journal of the American College of Cardiology has recognized the five-year follow-up results of the DEFER trial as one of the studies with the greatest impact on clinical cardiology in 2007. (JACC Vol. 51, No. 4, 2008 January 29, 2008:490-512)

PrimeWire(TM) and s5-FFR Option

Volcano is please
'/>"/>

SOURCE Volcano Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Volcano Presentation at Thomas Weisel Conference to Be Webcast
2. Volcano Corporation Schedules Second Quarter Conference Call, Webcast
3. Volcano Announces Acquisition of Novelis, Inc.
4. Volcano Announces Placement of 1,000th s5 and s5i IVUS Imaging System
5. Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter
6. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
7. Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR
8. Volcano Corporation Presentation at Cowen Healthcare Conference to be Webcast
9. Volcano Announces FDA 510(k) Clearance of Revolution Rotational Catheter and FFR for the s5i Integrated IVUS Console
10. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
11. Volcano Announces Closing of CardioSpectra Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... NC (PRWEB) March 06, 2015 ... innovative specialty CRO focused on specimen management and ... closed. , “Global Specimen Solutions, Inc. is excited ... management with investment that will further enhance our ... first-to-market services supporting specimen research. GSS has proved ...
(Date:3/6/2015)... -- BioSpecifics Technologies Corp. (NASDAQ: BSTC ), ... marketed as XIAFLEX ® (collagenase clostridium histolyticum or ... EU, announced today that it will host a conference ... on Friday, March 13, 2015 to report its fourth ... a corporate update. In order to ...
(Date:3/6/2015)... --  Senomyx , Inc. (NASDAQ: SNMX ), ... discover, develop, and commercialize novel flavor ingredients for the ... Poyhonen , the Company,s President and Chief Executive Officer, ... Chief Financial Officer, will present an overview of Senomyx,s ... at 2:00 p.m. Eastern Time (11:00 a.m. Pacific Time) ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 Transparency Market Research ... and Other Crops - Global Industry Analysis, Size, Share, Growth, ... the global isoxaflutole market was valued at US$ 116.3 Mn ... by 2020, expanding at a CAGR of 5.1% from 2014 ... isoxaflutole stood at 2,569.5 kilo tons in 2013. , Isoxaflutole ...
Breaking Biology Technology:Global Specimen Solutions, Inc. Closes Series A Funding 2Global Specimen Solutions, Inc. Closes Series A Funding 3BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2014 Financial Results on Friday, March 13, 2015 2SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE THE 27TH ANNUAL ROTH CONFERENCE 2Isoxaflutole Market is Expected to Reach US$ 163.0 Mn by 2020 : Transparency Market Research 2Isoxaflutole Market is Expected to Reach US$ 163.0 Mn by 2020 : Transparency Market Research 3
... WALTHAM, Mass., Dec. 11, 2011 Syndax Pharmaceuticals, ... a multicenter, phase 2 study, demonstrated entinostat, a novel, ... showed activity as a single agent in patients with ... being presented today, December 11, from 6:00 to 8:00 ...
... ANGELES, Dec. 9, 2011  Puma Biotechnology, Inc., a ... ongoing Phase II clinical trials of Puma,s investigational ... CTRC-AACR San Antonio Breast Cancer Symposium that is ... presentations are further detailed below: ...
... a heart surgeon at Gundersen Lutheran Health System ... an exciting technique, called minimally invasive coronary surgery ... very small three-inch cut is made between the ribs instead of ... with traditional open heart surgery. This means less pain and ...
Cached Biology Technology:Entinostat Demonstrates Activity in Hodgkin's Lymphoma 2Entinostat Demonstrates Activity in Hodgkin's Lymphoma 3Entinostat Demonstrates Activity in Hodgkin's Lymphoma 4Entinostat Demonstrates Activity in Hodgkin's Lymphoma 5Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium 2Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium 3Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium 4Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium 5Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium 6Gundersen Lutheran Offers Heart Surgery with Less Pain, Faster Recovery 2
(Date:3/5/2015)... , March 5, 2015 In Brazil ... of companies already using these solutions and 42 percent planning ... the latter, approximately 25 percent of the companies will be ... While the majority of companies in the region are currently ... the hybrid model will command significant attention in the coming ...
(Date:3/4/2015)... DUBLIN , Mar. 04, 2015 Research ... announced the addition of the "Global Biometrics ... their offering. The market for biometric ... CAGR of around 14% till 2020 ... will be increasing security needs, government projects and ...
(Date:3/3/2015)... March 3, 2015 Cryoport, Inc. ... advanced cryogenic logistics solutions for the life ... cells, cell lines, clinical research organizations, vaccine ... announced the expansion of its relationship with ... ("Fred Hutch") Clinical Research Division with the ...
Breaking Biology News(10 mins):Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... beetles and only two species of the tuatara, a reptile ... Crocodiles and alligators, while nearly 250 million years old, have ... including mammals and many species of birds and fish ... Scientists have often posited that because some ...
... of America (ESA) is pleased to announce the selection of ... Membership acknowledges those who have served ESA for at least ... Society that has reached an extraordinary level. Candidates for this ... voted on by the ESA membership. All four will be ...
... largely restricted to the eastern edge of the New England Tableland, and ... this flowering plant, until now classified as a variety of the Hairpin ... a distinct species. The study was published in the open access journal ... family of flowering plants that includes the Banksia and ...
Cached Biology News:Why are there so many species of beetles and so few crocodiles? 2Why are there so many species of beetles and so few crocodiles? 3Entomological Society of America names 2012 Honorary Members 2Entomological Society of America names 2012 Honorary Members 3Entomological Society of America names 2012 Honorary Members 4Botany student proves 'New England Banksia' a distinct species 2
... MitoPT kit is used in conjunction with your ... and induce apoptosis according to your existing procedure ... a negative control). Once you have induced apoptosis ... to each population and incubate the cells for ...
... The biolistic PDS-1000 He system ... gas to accelerate micron-size nucleic acid-coated ... necessary to transfect cells, tissues, or ... the cell surface. The system includes ...
Sf21 Insect Cells (Frozen) in Max-XP Medium...
... The MyCycler thermal cycler system is ... applications. This system includes the MyCycler personal ... module for use with 0.2 ml tubes ... options, and both algorithm and block modes ...
Biology Products: